On 22 July, Cross Country Healthcare, Inc. (NASDAQ:CCRN) announced it has entered into an agreement to amend its Second Lien Loan and Security Agreement. Cross Country Healthcare, Inc. (NASDAQ:CCRN) ended the last trading day at $12.06. Company weekly volatility is calculated as 3.30% and price to cash ratio as 51.73. Cross Country Healthcare, Inc. (NASDAQ:CCRN) showed a weekly performance of -6.37%.
On 22 July, 8×8 Inc. (NASDAQ:EGHT) reported financial results for the first quarter fiscal 2016 ended June 30, 2015. Total revenue of $47.9 million, including a one-time $1.2 million accelerated technology license payment, increased 26% year over year; service revenue of $44.2 million increased 29% year over year. On 24 July, 8×8 Inc. (NASDAQ:EGHT) shares fell -6.28% and was closed at $8.36. EGHT EPS growth in last 5 year was -19.70%. 8×8 Inc. (NASDAQ:EGHT) year to date (YTD) performance is -8.73%.
On 21 July, Gilead Sciences Inc. (NASDAQ:GILD) announced detailed 48-week data from an open-label Phase 3 study (Study 109) evaluating its investigational once-daily single tablet regimen (STR) of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg (E/C/F/TAF) among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate (TDF)-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48.Gilead Sciences Inc. (NASDAQ:GILD) shares fell -4.11% in last trading session and ended the day at $112.83. GILD Gross Margin is 86.00% and its has a return on assets of 42.70%. Gilead Sciences Inc. (NASDAQ:GILD) quarterly performance is 9.20%.
Research analysts at Citigroup Inc. assumed coverage on shares of Calithera Biosciences, Inc. (NASDAQ:CALA) in a report released on Friday. The firm set a “buy” rating on the stock. Calithera Biosciences, Inc. (NASDAQ:CALA) caters to the Healthcare space. Its weekly performance is 4.27%. On the last day of trading company shares ended up $9.03. Calithera Biosciences, Inc. (NASDAQ:CALA) distance from 50-day simple moving average (SMA50) is 4.57%.